Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery

Expert Opinion on Drug Discovery

Volumn 10, Issue 1, 2015, Pages 1-8

  Strebhardt, Klaus ^a,b   Becker, Sven ^a   Matthess, Yves ^b  

^a GOETHE UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cell cycle; Drug discovery; Kinase inhibitors; Polo like kinase

Indexed keywords

ADENOSINE TRIPHOSPHATE; POLO LIKE KINASE 1; POLO LIKE KINASE 2; POLO LIKE KINASE 3; POLO LIKE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE;

BIOLOGICAL FUNCTIONS; BLOOD FLOW; CANCER THERAPY; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; LEUKEMIA CELL; M PHASE CELL CYCLE CHECKPOINT; MOLECULAR BIOLOGY; NONHUMAN; PROTEIN DOMAIN; PROTEIN TARGETING; REVIEW; SPINDLE CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; ENZYMOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS;

EID: 84918811113     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2015.962510     Document Type: Review

References (35)

1. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010;9:643-60
2. Barr FA, Sillje HH, Nigg EA. Polo-like kinases and the orchestration of cell division. Nat Rev Mol cell biol 2004;5:429-40
3. Archambault V, Glover DM. Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol cell biol 2009;10:265-75
4. Holtrich U, Wolf G, Brauninger A, et al. Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci USA 1994;91:1736-40
5. Yuan J, Horlin A, Hock B, et al. Polo-like kinase, a novel marker for cellular proliferation. Am J Pathol 1997;150(4):1165-72
6. Wolf G, Hildenbrand R, Schwar C, et al. Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. Pathol Res Pract 2000;196(11):753-9
7. Kneisel L, Strebhardt K, Bernd A, et al. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol 2002;29(6):354-8
8. Strebhardt K, Kneisel L, Linhart C, et al. Prognostic value of pololike kinase expression in melanomas. JAMA 2000;283:479-80
9. Strebhardt K, Ullrich A. Targeting pololike kinase 1 for cancer therapy. Nat Rev Cancer 2006;6:321-30
10. Luo J, Emanuele MJ, Li D, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009;137:835-48
11. Raab M, Kappel S, Kramer A, et al. Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells. Nat Commun 2011;2:395
12. Kappel S, Matthess Y, Kaufmann M, Strebhardt K. Silencing of mammalian genes by tetracycline-inducible shRNA expression. Nature Protoc 2007;2:3257-69
13. Matthess Y, Kappel S, Spankuch B, et al. Conditional inhibition of cancer cell proliferation by tetracycline-responsive, H1 promoter-driven silencing of PLK1. Oncogene 2005;24:2973-80
14. Kappel S, Matthess Y, Zimmer B, et al. Tumor inhibition by genomically integrated inducible RNAi-cassettes. Nucleic Acids Res 2006;34:4527-36
15. Lenart P, Petronczki M, Steegmaier M, et al. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr biol 2007;17:304-15
16. Ma S, Charron J, Erikson RL. Role of Plk2 (Snk) in mouse development and cell proliferation. Mol Cell Biol 2003;23:6936-43
17. Burns TF, Fei P, Scata KA, et al. Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol 2003;23:5556-71
18. Holtrich U, Wolf G, Yuan J, et al. Adhesion induced expression of the serine/threonine kinase Fnk in human macrophages. Oncogene 2000;19:4832-9
19. Ouyang B, Pan H, Lu L, et al. Human Prk is a conserved protein serine/threonine kinase involved in regulating M phase functions. J Biol Chem 1997;272:28646-51
20. Wang Q, Xie S, Chen J, et al. Cell cycle arrest and apoptosis induced by human Polo-like kinase 3 is mediated through perturbation of microtubule integrity. Mol Cell Biol 2002;22:3450-9
21. Bahassi el M, Conn CW, Myer DL, et al. Mammalian Polo-like kinase 3 (Plk3) is a multifunctional protein involved in stress response pathways. Oncogene 2002; 21: 6633-40
22. Yang Y, Bai J, Shen R, et al. Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1 alpha under hypoxic conditions. Cancer Res 2008;68:4077-85
23. Raab M, Pachl F, Kramer A, et al. Quantitative chemical proteomics reveals a Plk1 inhibitor-compromised cell death pathway in human cells. Cell Res 2014;24(9):1141-5
24. Yuan J, Kramer A, Eckerdt F, et al. Efficient internalization of the polo-box of polo-like kinase 1 fused to an Antennapedia peptide results in inhibition of cancer cell proliferation. Cancer Res 2002;62:4186-90
25. Reindl W, Yuan J, Kramer A, et al. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem Biol 2008;15:459-66
26. Yuan J, Sanhaji M, Kramer A, et al. Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo. Am J Pathol 2011;179(4):2091-9
27. Elia AE, Cantley LC, Yaffe MB. Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates. Science 2003;299:1228-31
28. Reindl W, Strebhardt K, Berg T. A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1. Anal Biochem 2008;383:205-9
29. Yin Z, Song Y, Rehse PH. Thymoquinone blocks pSer/pThr recognition by Plk1 Polo-box domain as a phosphate mimic. ACS Chem Biol 2013;8:303-8
30. Liao C, Park JE, Bang JK, et al. Exploring potential binding modes of small drug-like molecules to the polo-box domain of human polo-like kinase 1. ACS med Chem Lett 2010;1:110-14
31. Kang YH, Park JE, Yu LR, et al. Self-regulated Plk1 recruitment to kinetochores by the Plk1-PBIP1 interaction is critical for proper chromosome segregation. Mol Cell 2006;24:409-22
32. Yun SM, Moulaei T, Lim D, et al. Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1. Nat Struct Mol Biol 2009;16:876-82
33. McInnes C, Estes K, Baxter M, et al. Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype. Mol Cancer Ther 2012;11:1683-92
34. Reindl W, Yuan J, Kramer A, et al. A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis. ChemBioChem 2009;10:1145-8
35. Dohner H, Lubbert M, Fiedler W, et al. Randomized, phase 2 trial comparing low-dose cytarabine with or without volasertib in AML patients not suitable for intensive induction therapy. Blood 2014;124(9):1426-33